Importing OTC Drugs and OTC Cosmetic-Drug Products into the United States
A practical guide for domestic and foreign manufacturers, exporters, private-label brands, importers, distributors and online sellers of sunscreens, antidandruff shampoos, fluoride toothpastes, antiperspirants, cold and cough medicines, laxatives, skin protectants, vaginal contraceptives, weight-control products and hand sanitizers.
OTC Drug Imports Require More Than Ordinary Consumer-Product Customs Clearance
Over-the-counter drug products are widely sold in pharmacies, supermarkets, convenience stores, dental offices, beauty stores, online marketplaces and direct-to-consumer websites. Because consumers may purchase them without a prescription, companies sometimes assume that these products are lightly regulated. The opposite is often true. An OTC drug must comply with the Federal Food, Drug, and Cosmetic Act, applicable FDA regulations, current good manufacturing practice requirements, establishment registration and drug listing obligations, labeling rules and the conditions of an applicable OTC monograph or approved drug application.
The compliance challenge becomes greater when the product is manufactured outside the United States. A foreign manufacturer may use ingredients, concentrations, terminology, claims or label formats accepted in its home country but not acceptable in the U.S. market. The product may also be offered under a private label owned by a U.S. distributor, Amazon seller, pharmacy brand or cosmetics company. Each participant may have a different commercial role, but no contract can prevent FDA from evaluating the actual manufacturing, labeling, import and distribution activities performed by each party.
Products such as sunscreen lotions, antidandruff shampoos, fluoride toothpastes and antiperspirant deodorants are especially easy to misclassify. They may perform a cosmetic function while also preventing disease or affecting the structure or function of the body. In that situation, they can be regulated as both cosmetics and drugs. The product must meet the requirements applicable to both categories rather than choosing whichever framework is easier.
This article explains the principal U.S. FDA compliance issues associated with importing and marketing common OTC drug categories. It also outlines how an experienced FDA consultant in the United States can assist manufacturers, exporters, importers, distributors and brand owners with regulatory planning, registration, listing, label review, facility readiness and import support.
Understanding the U.S. OTC Drug Regulatory Pathway
An OTC product is not automatically lawful merely because its active ingredient is familiar or the product is sold without a prescription in another country.
OTC Monograph Pathway
An OTC monograph establishes conditions under which products in a therapeutic category may be marketed without an individual approved new drug application. These conditions can address active ingredients, permitted concentrations, dosage forms, indications, directions, warnings, testing and other requirements. The finished product must conform to all applicable conditions, not merely contain a recognized ingredient.
Approved Application Pathway
A product that falls outside an applicable monograph may require an approved New Drug Application or Abbreviated New Drug Application before commercial marketing. This can include a different active ingredient, strength, route, dosage form, indication, patient population or combination. Some OTC drugs, including approved weight-loss products, reach the market through an application rather than a monograph.
Unapproved New Drug Risk
A product marketed outside a lawful monograph or approved application may be considered an unapproved new drug. Registration, drug listing, an NDC, customs entry or marketplace acceptance does not cure that defect. FDA can detain imported shipments, issue warning letters, place firms on import alert, request recalls or pursue other enforcement measures.
OTC Cosmetics and Dual-Regulated Products
“OTC cosmetics” is a useful commercial phrase, but it is not a separate legal category that replaces the drug rules. In the United States, a product may be a cosmetic, a drug, or both. The intended use is determined from the product’s claims, labeling, website, social media, advertisements, consumer perception and other evidence. A shampoo promoted only to cleanse or beautify hair may be a cosmetic. A shampoo promoted to control dandruff is also a drug. A deodorant intended only to mask odor may be a cosmetic, while a deodorant that reduces perspiration is an antiperspirant drug and cosmetic combination.
Companies marketing dual-regulated products must evaluate both systems. Drug requirements may include monograph conformity, CGMP, facility registration, drug listing and Drug Facts labeling. Cosmetic requirements may include ingredient declaration, responsible person obligations, safety substantiation, adverse event handling, facility registration or product listing requirements under the Modernization of Cosmetics Regulation Act when applicable, and restrictions on color additives and prohibited ingredients.
Sunscreen Cosmetics
Moisturizers, foundations, lip products and makeup promoted with sun-protection claims can become both cosmetics and sunscreen drugs.
Antidandruff Shampoo
The cleansing and beautifying functions are cosmetic, while dandruff-control claims create a drug intended use.
Fluoride Toothpaste
Cleaning and freshening are cosmetic functions; anticaries or therapeutic claims trigger drug requirements.
Antiperspirant Deodorant
Odor masking is cosmetic, while perspiration reduction is a drug function subject to antiperspirant conditions.
Major OTC Product Categories and Category-Specific Risks
Sunscreen Products
Sunscreens are drugs because they are intended to prevent sunburn and reduce risks associated with ultraviolet exposure. A lotion, spray, stick, cream, makeup or moisturizer with SPF or sunburn-prevention claims must be evaluated under the applicable sunscreen requirements. Compliance depends on permitted active ingredients and concentrations, broad-spectrum and SPF testing, dosage form, directions, warnings, water-resistance claims and Drug Facts labeling.
Foreign formulas often require special review because ultraviolet filters permitted elsewhere may not be permitted for monograph marketing in the United States. A product should not be shipped merely because it passed testing under European, Asian, Canadian or Australian standards.
Antidandruff Shampoo
Antidandruff shampoos combine cosmetic cleansing with drug treatment claims. The active ingredient, concentration, directions and warning statements must fit the applicable dandruff or seborrheic dermatitis conditions. Claims such as “eliminates fungus,” “treats scalp infection,” “cures psoriasis” or “permanently stops hair loss” may exceed the lawful scope and create unapproved drug concerns.
Batch testing, active-ingredient assay, microbial controls, stability, packaging compatibility and label consistency are central because a familiar cosmetic-style container does not reduce pharmaceutical quality obligations.
Fluoride Toothpaste
Toothpaste containing fluoride or making anticavity claims is an OTC drug as well as a cosmetic. Compliance considerations include the identity and concentration of the anticaries active ingredient, available fluoride, pH, abrasivity, dosage instructions, age-related directions, warnings, Drug Facts content and packaging statements. Products making whitening, sensitivity, gingivitis, plaque or enamel-repair claims may require additional classification analysis.
Manufacturers should confirm that flavor names, sweeteners, botanical ingredients and promotional claims do not obscure required warnings or imply disease-treatment benefits beyond the applicable conditions.
Antiperspirant Deodorant
An antiperspirant reduces perspiration and is regulated as a drug; a deodorant primarily controls odor and may be cosmetic. Products that do both must comply with both frameworks. Active aluminum ingredients, concentration calculations, dosage form, directions, warnings and effectiveness claims require careful review.
Aerosols, roll-ons, sticks, creams and wipes may present different manufacturing and packaging risks. Claims such as “72-hour clinical protection,” “medical strength” or therapeutic statements involving hyperhidrosis should be supported and evaluated for consistency with the product’s regulatory status.
Cold and Cough Products
Cold, cough, allergy, bronchodilator and related products are highly claim-sensitive. A multi-symptom formula may include analgesic, antitussive, expectorant, antihistamine or decongestant ingredients. Each active ingredient must be permitted for the intended route, patient population and combination, and the label must avoid duplication or unsafe dosing instructions.
Pediatric claims, nighttime claims, alcohol content, measuring devices, combination warnings, drowsiness statements and interactions require particular attention. Importers should never assume that a popular non-U.S. cough syrup can be relabeled for the American market without a complete formulation and monograph assessment.
Laxatives
Laxative products may operate through bulk-forming, stimulant, osmotic, saline, lubricant, stool-softening or other mechanisms. Their active ingredients, dosage forms, directions, onset statements and warnings vary. Products sold as teas, gummies, powders, capsules or herbal cleanses can still be drugs when intended to relieve constipation or stimulate bowel evacuation.
Claims involving “detoxification,” rapid weight reduction, colon cleansing or chronic use can create additional risk. The manufacturer must control identity, potency, microbiological quality and dose uniformity, particularly for botanical materials and powders.
Skin Protectants
Skin protectants include products intended to temporarily protect minor cuts, scrapes, burns, chapped skin, cracked skin or irritation. Common dosage forms include ointments, creams, pastes, balms and powders. Ingredients such as petrolatum, dimethicone, zinc oxide, colloidal oatmeal and others may be eligible when used under applicable conditions.
Statements involving eczema treatment, wound healing, infection prevention, pain relief or scar removal may change the regulatory analysis. Baby-care products, diaper-rash products and barrier creams also need close review of intended use, active-ingredient percentage, warnings and directions.
Vaginal Contraceptives
OTC vaginal contraceptive products require exact conformity with applicable conditions concerning active ingredients, dosage form, administration, directions, warnings and effectiveness-related statements. These products involve sensitive consumer instructions and must clearly communicate use before intercourse, repeat dosing, limitations and sexually transmitted infection information where required.
Foreign manufacturers should evaluate applicators, unit-dose packaging, leakage, stability, microbial controls and compatibility between the formulation and delivery system. Promotional claims must not overstate pregnancy-prevention effectiveness or imply protection that the product does not provide.
Weight-Control Products
Weight-control claims require exceptional caution. FDA’s historical OTC weight-control rulemaking concluded that there are no generally recognized as safe and effective active ingredients under the weight-control monograph. Consequently, a company should not assume that a capsule, tea, gum, patch or appetite suppressant can be marketed as a monograph OTC weight-loss drug.
Some weight-loss medicines are lawfully sold OTC under an approved application, such as OTC orlistat products, but application-specific conditions, labeling and risk information apply. Other products may be dietary supplements, foods or devices depending on their composition and intended use. Classification must occur before importation and claim development.
Hand Sanitizers
Hand sanitizers promoted to reduce bacteria on the skin are OTC topical antiseptic drugs. Consumer antiseptic rub products using eligible active ingredients still require complete compliance with applicable OTC conditions, CGMP, registration, listing and labeling. Temporary pandemic-era enforcement policies should not be treated as permanent authorization.
FDA enforcement has repeatedly focused on methanol contamination, inadequate alcohol concentration, substitution of technical-grade ingredients, poor testing, misleading viral claims and insanitary manufacturing. Each lot should be supported by reliable identity, strength, purity and impurity testing, including appropriate controls for alcohol raw materials.
Drug Establishment Registration, U.S. Agent and Drug Listing
Domestic and foreign establishments that manufacture, repack or relabel drugs for U.S. commercial distribution generally must register with FDA and renew their registration annually. A foreign drug establishment whose products are imported or offered for import must register before offering the drugs for import. The foreign establishment must identify a U.S. Agent and provide required information about known U.S. importers.
Registration should accurately describe the establishment’s operations. The legal manufacturer, contract manufacturer, packer, repacker, relabeler and other participating sites must be evaluated based on actual activities. A brand owner cannot simply register one office and ignore the facilities performing regulated manufacturing or packaging work.
Commercially marketed drug products must also be listed electronically with FDA. Drug listing submissions contain structured information concerning the labeler, product, active ingredients, dosage form, route, marketing category, package configurations and labeling. National Drug Code numbers are associated with the listing system, but an NDC is not an approval number and must never be advertised as proof of FDA approval.
OMUFA Facility Fees and OTC Monograph Obligations
The Over-the-Counter Monograph Drug User Fee Program, commonly called OMUFA, supports FDA’s administration of the modernized OTC monograph system. Certain qualifying facilities that manufacture or process finished OTC monograph drug products may be responsible for annual facility fees. Contract manufacturing organizations may be subject to a different fee rate. Companies should determine whether each site is a monograph drug facility, contract manufacturing organization or otherwise outside the fee definition.
For fiscal year 2026, FDA stated that OTC monograph drug facility fees were due June 1, 2026. Fee amounts and deadlines can change each fiscal year, and late or unpaid fees can affect the status of a facility and the lawfulness of products associated with it. Registration and fee obligations therefore should be managed as a coordinated annual compliance calendar rather than unrelated administrative tasks.
OMUFA also includes fees for certain OTC Monograph Order Requests. A company seeking to add or change a monograph condition may require an administrative order process rather than simply launching the product. Regulatory strategy should distinguish routine monograph conformity from a request that asks FDA to modify the recognized conditions of use.
Determine Fee Status
Review each facility’s activities, dosage forms and commercial role to determine whether an annual OMUFA facility fee applies.
Track Deadlines
Maintain a calendar for registration renewal, facility-fee notices, drug-listing updates and product discontinuation reporting.
Retain Evidence
Keep payment confirmations, FDA correspondence, registration records and fee-status analyses with the regulatory file.
Current Good Manufacturing Practice Applies to OTC Drugs
OTC status does not create an exemption from pharmaceutical manufacturing controls. Finished OTC drugs are subject to current good manufacturing practice requirements, including 21 CFR Parts 210 and 211. FDA applies these requirements to domestic and foreign facilities. A modern quality system should cover qualified personnel, facilities, equipment, sanitation, components, containers, closures, production controls, laboratory controls, stability, complaints, investigations, records, returns and recalls.
Private-label brands and importers often depend heavily on a contract manufacturer’s certificate of analysis. A certificate can be useful, but it does not replace supplier qualification, written specifications, scientifically sound methods or the testing responsibilities imposed on the manufacturer. High-risk categories require additional controls. Hand sanitizers need robust alcohol identity and impurity testing. Sunscreens require validated SPF and broad-spectrum testing where applicable. Toothpastes need control of available fluoride. Multi-ingredient cough and cold products require accurate active-ingredient assay and dose uniformity.
Raw Materials
Identity, strength, quality, purity, supplier qualification and contamination risk.
Production
Master records, batch records, line clearance, reconciliation and process controls.
Laboratory
Validated or suitable methods, specifications, stability, out-of-specification investigations and data integrity.
Postmarket
Complaints, adverse events, trend review, returns, recalls and corrective and preventive actions.
OTC Drug Labeling, Drug Facts and Promotional Claims
Most nonprescription drug labels use the standardized Drug Facts format. Depending on the product, required information can include active ingredient and purpose, uses, warnings, directions, other information and inactive ingredients. The principal display panel, package size, net quantity, statement of identity, responsible company information and tamper-evident packaging statements may also be relevant. Required content must be legible, conspicuous and presented in the correct order and format.
Translations from foreign labels should not be performed word for word without regulatory analysis. The U.S. indication, warnings, directions and age limits may differ. A package may also need sufficient space for the complete Drug Facts panel, which can affect carton dimensions, bottle labels, peel-back labels and multipanel packaging.
FDA evaluates intended use across the entire marketing environment. Websites, Amazon pages, TikTok Shop listings, social media posts, influencer scripts, videos, brochures, search advertisements and distributor materials can establish drug claims. Statements such as “kills viruses,” “repairs eczema,” “stops hair loss,” “clinically cures infection,” “blocks all UV damage” or “guaranteed weight loss” may exceed a monograph or approved labeling.
Label Conformity
Match the active ingredients, strengths, purposes, uses, warnings, directions and package configurations to the lawful pathway.
Claim Control
Create an approved-claims library for packaging, websites, marketplaces, distributors and influencers.
Change Control
Review reformulations, new flavors, package redesigns, claims, suppliers and dosage forms before implementation.
Import Entry, FDA Review, Detention and Import Alerts
Imported OTC drugs must satisfy the same federal standards that apply to domestically produced drugs. At entry, FDA may review information transmitted through U.S. Customs and Border Protection systems, including manufacturer identity, product codes, declared descriptions, registration data, drug listing information and shipment details. Inconsistent or incomplete information can delay entry even when the underlying product is compliant.
FDA may examine the shipment, collect samples or request records. The agency may detain products that appear to be unapproved, misbranded, adulterated, manufactured at an unregistered establishment, not properly listed or associated with a facility having significant compliance concerns. Products may also be subject to detention without physical examination when the manufacturer, product or category is covered by an import alert.
The Importer of Record for customs purposes is not automatically the same as the FDA-designated U.S. Agent, labeler, drug sponsor or distributor. Contracts should identify each role clearly, but entry data must still reflect the actual transaction and regulated entities. The importer should have access to registration records, listing files, labels, batch documents, certificates of analysis and contact persons before the shipment arrives.
Pre-Import Review
Classify the product, confirm the lawful marketing pathway and audit the formula and claims.
Verify FDA Data
Confirm registration, U.S. Agent, drug listing, NDC presentation and responsible facility information.
Prepare Entry Records
Align invoices, product descriptions, manufacturer data, shipping records and entry declarations.
Respond Rapidly
Coordinate records and regulatory responses if FDA requests information, samples or testimony.
Responsibilities of Manufacturers, Exporters, Importers and Distributors
Domestic and Foreign Manufacturers
Manufacturers are responsible for designing and operating compliant production and quality systems. They must use suitable components, validated or appropriate methods, controlled records, qualified personnel, stable formulations and reliable investigations. Foreign facilities must also maintain registration, U.S. Agent and importer information when required.
Exporters and Trading Companies
Exporters should not alter labels, manufacturers, invoices or product descriptions without regulatory review. They should confirm that the actual manufacturing establishment is disclosed and that shipment documents do not create inconsistencies with FDA registrations or listings.
U.S. Importers and Brand Owners
Importers and brands should perform due diligence before purchase orders are issued. This includes verifying the formula, regulatory pathway, registration, drug listing, quality agreement, specifications, batch release package, claims and entry information. Marketplace acceptance is not a substitute for FDA compliance.
Distributors and Online Sellers
Distributors control how products are promoted and stored. They should maintain approved claims, lot traceability, complaint procedures, adverse event escalation, recall cooperation and storage controls. Online listings must remain consistent with the physical label and lawful intended use.
Common Reasons OTC Products Face FDA Enforcement
Wrong Regulatory Classification
A cosmetic or supplement is promoted with drug claims, or a foreign OTC formula is assumed to fit a U.S. monograph without analysis.
Nonconforming Formula
The active ingredient, concentration, dosage form, route, combination or indication falls outside the applicable monograph or approval.
CGMP Deficiencies
Inadequate testing, poor investigations, unreliable laboratory data, deficient supplier controls or incomplete batch documentation.
Registration or Listing Errors
An establishment is missing, operations are inaccurate, annual renewal was not completed or the product listing does not match the marketed label.
Misleading NDC or FDA Claims
The company represents an NDC, registration number or database entry as FDA approval or certification.
Import Data Mismatch
The manufacturer, product code, labeler, shipment description, listing or invoice information conflicts across the entry record.
Services Provided by FDA Consultants in the United States
An FDA consultant can help a company organize complex requirements into a practical market-entry and maintenance program. The consultant does not replace the manufacturer’s legal responsibility, quality unit or management, and cannot guarantee FDA acceptance. The consultant can, however, identify gaps early, coordinate submissions, improve documentation and reduce avoidable import and enforcement risk.
Product Classification
Determine whether the product is a cosmetic, OTC drug, prescription drug, dietary supplement, device or combination, and identify the likely marketing pathway.
Monograph Assessment
Compare active ingredients, concentrations, dosage form, route, indications, directions, warnings and testing with current OTC conditions.
FDA Registration
Assist domestic and foreign establishments with electronic registration, annual renewal, operation codes and facility-information maintenance.
U.S. Agent Service
Serve as the communication contact for a foreign drug establishment and help route FDA communications to responsible company personnel.
Drug Listing and NDC
Prepare or review structured drug listing data, package configurations, labeler information, labeling files and updates.
Label and Claims Review
Review Drug Facts panels, principal display panels, package statements, websites, marketplace pages and promotional content.
CGMP Gap Assessment
Evaluate quality systems, SOPs, specifications, testing, batch records, stability, complaints, investigations and data integrity.
Inspection Readiness
Conduct mock inspections, develop document-request systems, prepare subject-matter experts and help organize corrective actions.
Import Support
Review entry information, coordinate documentation, analyze detentions and help prepare responses to FDA import inquiries.
OMUFA Support
Assess facility-fee status, maintain annual deadlines and organize payment and registration records.
Complaint and Recall Systems
Develop procedures for complaints, adverse events, escalation, traceability, market withdrawals and recalls.
Ongoing Compliance
Monitor changes in formulas, suppliers, labels, claims, manufacturing sites, FDA requirements and marketplace activities.
A Practical OTC Drug Import Compliance Program
A strong import program begins before product development is finalized. Regulatory requirements can influence active ingredients, packaging dimensions, testing methods, marketing language, manufacturing contracts and landed cost. Discovering a nonconforming formula after thousands of units have been produced is significantly more expensive than conducting a pre-formulation or pre-label review.
Classify
Identify the product category, intended use, monograph or application pathway and dual cosmetic-drug status.
Qualify
Evaluate the manufacturer, quality system, testing capabilities, regulatory history and supply chain.
Register and List
Complete required facility registration, U.S. Agent designation, drug listing and fee activities.
Verify the Label
Review Drug Facts, claims, package configuration, NDC presentation and online marketing.
Release the Batch
Confirm specifications, test results, deviations, stability status, packaging and shipment documentation.
Prepare the Entry
Align customs and FDA data with the actual manufacturer, importer, product and listing information.
Monitor the Market
Control advertising, complaints, adverse events, distribution, storage and changes to the product.
Renew and Improve
Complete annual obligations, internal reviews, training, corrective actions and regulatory updates.
Successful OTC Drug Imports Depend on Product, Facility and Supply-Chain Compliance
The U.S. OTC market offers substantial opportunities for pharmaceutical manufacturers, personal-care companies, private-label brands and international exporters. However, market access depends on more than a commercial agreement or a customs broker. The product must have a lawful regulatory pathway, the formulation must conform to the relevant conditions, the establishment must meet registration and manufacturing obligations, the listing must be accurate, the label must be compliant and the imported shipment must be supported by consistent documentation.
Sunscreens, antidandruff shampoos, fluoride toothpastes and antiperspirant deodorants illustrate why classification matters. These familiar products may be both cosmetics and drugs. Cold and cough medicines, laxatives, skin protectants and vaginal contraceptives require category-specific attention to ingredients, uses, warnings and directions. Weight-control products require particular caution because broad weight-loss claims do not create a lawful monograph pathway. Hand sanitizers demand rigorous identity, potency and contamination controls because failures can create immediate public-health risks.
Domestic and foreign manufacturers, exporters, importers and distributors should therefore treat OTC compliance as a connected system. Regulatory affairs, quality, labeling, logistics, customs entry, e-commerce content, complaints and annual FDA maintenance must work together. A knowledgeable FDA consultant can help the parties identify gaps, assign responsibilities and develop documentation before those gaps become rejected entries, import alerts, warning letters or recalls.
Prepare Your OTC Drug Product Before It Reaches the U.S. Border
ITB HOLDINGS LLC assists domestic and foreign companies with OTC product classification, FDA establishment registration, U.S. Agent service, drug listing, NDC-related submissions, label and claims review, CGMP readiness, OMUFA support and import compliance coordination.
Whether you manufacture sunscreen, fluoride toothpaste, antidandruff shampoo, antiperspirant, cough medicine, laxatives, skin protectants, vaginal contraceptives, approved weight-control drugs or hand sanitizers, a premarket compliance review can identify costly issues before production, shipment or marketplace launch.
